Family PracticeNursingOBGYN & Women's HealthPediatricsPulmonologyInternal MedicineCritical CareEmergency MedicinePathologyPharmacyCenters For Disease ControlPublic HealthVaccinesInfectious DiseaseCoronavirus
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Sept. 4, 2020 (HealthDay News) -- The chief adviser for the White House vaccine program said Thursday it was "extremely unlikely, but not impossible" that a COVID-19 vaccine could be available by the end of October.
Speaking with National Public Radio, Moncef Slaoui, M.D., said that the U.S. Centers for Disease Control and Prevention guidance to states to prepare for a vaccine as early as late October was "the right thing to do" in case a vaccine was ready by that time. "It would be irresponsible not to be ready if that was the case," Slaoui said, adding that he first heard about the new CDC guidance from media reports, the Washington Post said. Still, Slaoui, the chief scientific adviser for Operation Warp Speed, described getting a vaccine by late October as a "very, very low chance."
Slaoui did confirm that the two main vaccine candidates, referred to as Vaccine A and Vaccine B by the CDC, were being developed by Pfizer and Moderna, respectively. He added that there was "no intent" to introduce a vaccine before clinical trials were completed. The trials would only be completed when an independent safety monitoring board affirmed the effectiveness of the vaccine, he said.
While expressing doubt about an October timeline, Slaoui believes "that we will have a vaccine available before the end of the year and it will be available in quantities that can immunize patients, subjects at the highest risk." By the end of the year, there should be enough doses of the vaccine ready to immunize "probably between 20 and 25 million people." There should be enough doses to immunize the U.S. population "by the middle of 2021," he added.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 25, 2022
Read this Next
Other Trending Articles